Aims Vinflunine is a novel tubulin‐targeted inhibitor indicated as a single agent for the
treatment of bladder cancers after failure of prior platinum‐based therapy. Its …

Vinflunine is a novel tubulin-targeted agent that is currently indicated as a monotherapy in
bladder cancer patients. The recommended dose of 320 mg/m 2 is given as an intravenous …

Abstract C145 Background: Vinflunine (VFL) is a new microtubule inhibitor of the vinca
alkaloid class, which is active in several tumour types especially in platinum-refractory …

Vinflunine is a novel bifluorinated vinca alkaloid that appears to differ from other class
members in terms of its tubulin-binding properties and inhibitory effects on microtubule …

Aims Vinflunine (VFL) ditartrate, a novel tubulin‐targeted inhibitor, is registered for the
treatment of patients with advanced or metastatic urothelial transitional cell carcinoma. This …

Background: Vinflunine is a new-generation microtubule inhibitor, which is currently
registered in Europe and in some countries elsewhere as an intravenous formulation for the …

OBJECTIVE: Vinflunine (VFL) is a novel microtubule inhibitor indicated in the treatment of
advanced or metastatic urothelial transitional cell cancer after failure of a prior platinum …

A multicentre phase II trial to determine the efficacy of vinflunine as second-line therapy in
patients with advanced transitional cell carcinoma (TCC) of the bladder; secondary …

Purpose Intravenous vinflunine 320 mg/m 2 every 3 weeks plus best supportive care
resulted in better overall survival in comparison with best supportive care alone for eligible …

Background Vinflunine is recommended in the European guideline for the treatment of
advanced or metastatic urothelial cell carcinoma (UCC) after failure of platinum-based …